UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsUpgradesPrice TargetHot
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.